DFDS A/S
Company announcement no. 8 |
DFDS’ long-term incentives for management aims to link remuneration to the sustained performance of the company, as reflected in the share price, whilst also supporting the retention of management.
Today, the Board of Directors have awarded Torben Carlsen, CEO, 5,774 restricted share units (RSU) and 37,037 share options, and Karina Deacon, CFO, 3,070 RSUs and 19,691 share options. In addition, a total of 15,260 RSUs and 97,898 share options were awarded to a number of key employees. The award of RSUs is subject to the approval of a revised remuneration policy at the coming annual general meeting.
The share options and the RSUs vest with 1/36 per month from and including February 2021. The share options may be exercised in the period from February 2024 until February 2026. The share price at grant and the exercise price are based on the volume weighted average share price of DFDS shares traded on NASDAQ Copenhagen on the five trading days immediately following the publication of DFDS’ most recent financial report to the time of grant. The share price at grant for the RSU’s has been calculated at 273.65 and for the share options, 10% has been added, giving an exercise price of DKK 301 per share of DKK 20 nominal value. The total value of the award of the RSUs and the share options, calculated according to the Black-Scholes model as described in DFDS’ most recent remuneration policy, is DKK 13.2m, including the awards to the CEO and the CFO.
Contact
Karina Deacon, CFO, +45 33 42 33 42
Søren Brøndholt Nielsen, IR, +45 33 42 33 59
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom